These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Insulin and arterial hypertension: role of hypersympathicotonia]. Oganov RG; Aleksandrov A Ter Arkh; 2002; 74(12):5-7. PubMed ID: 12577828 [No Abstract] [Full Text] [Related]
4. [Insulin resistance and cardiovascular complications]. Janka HU Wien Klin Wochenschr; 1994; 106(24):758-62. PubMed ID: 7846894 [TBL] [Abstract][Full Text] [Related]
5. Resistance exercise training: its role in the prevention of cardiovascular disease. Braith RW; Stewart KJ Circulation; 2006 Jun; 113(22):2642-50. PubMed ID: 16754812 [No Abstract] [Full Text] [Related]
6. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Chapman MJ; Sposito AC Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of vascular disease in hypertension with special reference to diabetes. Yudkin JS Semin Vasc Med; 2002 May; 2(2):139-48. PubMed ID: 16222605 [TBL] [Abstract][Full Text] [Related]
8. Insulin resistance and hypertension. Patients in double jeopardy for cardiovascular disease. McLaughlin T; Reaven G Geriatrics; 2000 Jun; 55(6):28-32, 35. PubMed ID: 10872343 [TBL] [Abstract][Full Text] [Related]
10. [Arterial hypertension, insulin resistance, and cardiovascular diseases]. Ferrannini E G Ital Cardiol; 1990 Sep; 20(9):791-4. PubMed ID: 2079179 [No Abstract] [Full Text] [Related]
11. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk. Chan JC; Tong PC; Critchley JA Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595 [TBL] [Abstract][Full Text] [Related]
12. Interferon regulatory factor signalings in cardiometabolic diseases. Zhang XJ; Zhang P; Li H Hypertension; 2015 Aug; 66(2):222-47. PubMed ID: 26077571 [No Abstract] [Full Text] [Related]
13. Microvascular dysfunction: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. De Boer MP; Meijer RI; Wijnstok NJ; Jonk AM; Houben AJ; Stehouwer CD; Smulders YM; Eringa EC; Serné EH Microcirculation; 2012 Jan; 19(1):5-18. PubMed ID: 21883642 [TBL] [Abstract][Full Text] [Related]
14. Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease. Zhou MS; Schulman IH; Zeng Q Vasc Med; 2012 Oct; 17(5):330-41. PubMed ID: 22814999 [TBL] [Abstract][Full Text] [Related]
15. Hypertension and the metabolic cardiovascular syndrome: special reference to premenopausal women. Os I; Nordby G J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S15-21. PubMed ID: 1283764 [TBL] [Abstract][Full Text] [Related]
16. Insulin and blood pressure regulation. Gans RO; Donker AJ J Intern Med Suppl; 1991; 735():49-64. PubMed ID: 2043223 [TBL] [Abstract][Full Text] [Related]
18. Microvascular dysfunction: causative role in the association between hypertension, insulin resistance and the metabolic syndrome? Serné EH; de Jongh RT; Eringa EC; Ijzerman RG; de Boer MP; Stehouwer CD Essays Biochem; 2006; 42():163-76. PubMed ID: 17144887 [TBL] [Abstract][Full Text] [Related]
19. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Jonk AM; Houben AJ; de Jongh RT; Serné EH; Schaper NC; Stehouwer CD Physiology (Bethesda); 2007 Aug; 22():252-60. PubMed ID: 17699878 [TBL] [Abstract][Full Text] [Related]
20. Diabetes and hypertension: a review. Sowers JR; Khoury S Prim Care; 1991 Sep; 18(3):509-24. PubMed ID: 1658839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]